USPatentGranted
B2

Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases

Granted 23 Feb 2016 · 6 office actions

Life of the patent

3 dated events
⤢ drag to zoomJan 2013Jul 2013Jan 2014Jul 2014Jan 2015Jul 2015Jan 2016Prosecution
Prosecutionhover for detail · click to open

Abstract

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. [structure]

Claims

26 · 2 independent · depth 3
1234567891011121314151617181920212223242526
26 granted claims

Classifications

8 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K31/5383
  • A61K31/5377
  • A61K45/06
  • A61K31/506
Section C — Chemistry; metallurgy
  • C07D413/14
  • C07D498/04
  • C07D401/14
  • C07D405/14

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency
3.4 y
1,237 days filing → grant
Office actions
3
non-final + final
Responses
4
2 RCE
Examiner
Deepak Rao
art unit 1624 · TC 1600
Citations: 8 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Log in to unlock

Priority chain

1 priority documents
›Priority documents — 1
TypeDocumentDate
related publicationUS 20140249133 A14 Sep 2014

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Log in to unlock

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.

Log in to unlock